2. Resilience: $625 million (Diagnostics/Tools)
Resilience CEO Rahul Singhvi (blue shirt) with employees of the biomanufacturing firm [Photo courtesy of Resilience]
La Jolla, California-based Resilience said it has around 1,700 employees and 1 million square feet of manufacturing space across 11 locations. The company has raised more than $2 billion since its founding in 2020, including a $600 million Series C round in 2021.
“We have an ambitious goal to reinvent biomanufacturing by bringing new processes and technologies to an industry that hasn’t kept pace with the explosive innovation in drug discovery,” Resilience CEO Rahul Singhvi said when announcing the Series D funding round. “While we recognize that our goal is neither quick nor easy, we are driven by our mission to democratize access to medicines. These new funds will help support our next phase of growth, as we continue to innovate biomanufacturing across all our modalities, expand our footprint to serve customers, sign strategic collaborations and support the developers of a new generation of complex medicines.”
In November, Resilience announced it had a deal to purchase an AstraZeneca manufacturing facility in West Chester, Ohio to make medicines for AstraZeneca through a multi-year supply agreement. That deal — including the transfer of the 580,000-square-foot facility and its 500 employees — was scheduled to close in early 2023.
“We envision the West Chester site as our global center of excellence for commercial drug product manufacturing that will produce a wide range of life-saving medicines,” Singhvi said. “This partnership is an exciting step toward our mission of broadening patient access to complex medicines and protecting domestic biopharmaceutical supply chains.”
